Adamis Pharmaceuticals Corp is a specialty biopharmaceutical company focused on developing and commercializing products in various therapeutic areas, including respiratory disease and allergy. The company's Symjepi (epinephrine) Injection 0.3mg and Symjepi (epinephrine) Injection 0.15 mg products were approved for use in the emergency treatment of acute allergic reactions, including anaphylaxis. It previously announced a distribution and commercialization agreement with Sandoz to market Symjepi in the US. The company is developing additional products, including a sublingual tadalafil product candidate for the treatment of erectile dysfunction, a naloxone injection product for the treatment of opioid overdose, and metered dose inhaler and dry powder inhaler product candidates.
San Diego, CA, 92130